Skip to main
AAPG

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group is a clinical-stage biotechnology company with a positive outlook, supported by a strong pipeline of drugs and approved treatments for cancer, a solid financial position and partnerships for success. The company's focused approach on developing therapies for hematologic malignancies, coupled with a talented workforce and dedicated board of directors, suggest potential for long-term growth and success. However, it also faces competition and risks in the biopharmaceutical industry, which should be carefully monitored.

Bears say

Ascentage Pharma Group is a clinical-stage biotechnology company developing novel therapies for cancer, hepatitis B, and age-related diseases. Despite their promising early-stage treatments and multiple partnerships, potential risks from competition, currency fluctuations, and challenges in clinical trials could hinder their success. The effectiveness of their third-generation TKI, olverembatinib, is promising but faces challenges in its off-target effects and potential resistance mutations. Their success in the competitive biotech market ultimately hinges on successfully bringing their treatments to market and achieving favorable economics.

AAPG has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Buy based on their latest research and market trends.

According to 4 analysts, AAPG has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.